Browse by author
Lookup NU author(s): Dr Balasubramanian Ravikumar, Jean Gerrard, Dr Michael FirbankORCiD, Annette Lane, Professor Roy Taylor
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Objective: Hepatic triglyceride is closely associated with hepatic insulin resistance and is known to be decreased by thiazolididinediones. We studied the effect of pioglitazone on hepatic triglyceride content and the consequent effect on postprandial endogenous glucose production (EGP) in type 2 diabetes. Research Design and Methods: Ten subjects with type 2 diabetes on sulfonylurea therapy were treated with pioglitazone (30 mg daily) for 16 weeks. EGP was measured using a dynamic isotopic methodology after a standard liquid test meal both before and after pioglitazone treatment. Liver and muscle triglyceride levels were measured by H-1 magnetic resonance spectroscopy, and intra-abdominal fat content was measured by magnetic resonance imaging. Results: Pioglitazone treatment reduced mean plasma fasting glucose and mean peak postprandial glucose levels. Fasting EGP decreased after pioglitazone treatment (16.6 +/- 1.0 vs. 12.2 +/- 0.7 mu mol center dot kg(-1) center dot min(-1), P = 0.005). Between 80 and 260 min postprandially, EGP was twofold lower on pioglitazone (2.58 +/- 0.25 vs. 1.26 +/- 0.30 mu mol center dot kg(-1) center dot min(-1), P
Author(s): Ravikumar B, Gerrard J, Man CD, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R
Publication type: Article
Publication status: Published
Journal: Diabetes
Year: 2008
Volume: 57
Issue: 9
Pages: 2288-2295
ISSN (print): 0012-1797
ISSN (electronic): 1939-327X
Publisher: American Diabetes Association
URL: http://dx.doi.org/10.2337/db07-1828
DOI: 10.2337/db07-1828
Altmetrics provided by Altmetric
